Policy Watch: 20 Regulatory Updates — June 22, 2026

Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I

The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.

Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I

The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis.

Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as adulterant in illicit cannabis products, into Schedule I, impacting handling and potentially raising concerns for patient safety due to misidentification.

Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act

The DEA placed five benzodiazepine analogs into Schedule I, impacting potential clinical considerations for practitioners evaluating patient-reported use of these substances alongside cannabis.

Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I

The DEA temporarily placed 2-fluorodeschloroketamine into Schedule I, potentially impacting research and clinical use should this substance be considered as an adjunct therapy alongside cannabis for certain conditions.

Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I

The DEA placed 4-fluoroamphetamine into Schedule I, potentially impacting research access and clinical use should similar scheduling actions occur with cannabinoids or related compounds.

Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I

The DEA placed potent synthetic opioids N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians who may encounter patients with co-prescribed medications or polysubstance use disorders.

Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

The DEA placed two synthetic opioids, N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene, into Schedule I, impacting clinicians needing to differentiate these substances from cannabis when assessing patient substance use or toxicology results.

Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I

The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.

Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as adulterant in illicit cannabis products, into Schedule I, impacting its legality and clinical use.

Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I

The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.

Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I

The DEA placed 4-chloromethcathinone, a synthetic cathinone unrelated to cannabis, into Schedule I, impacting clinicians by restricting research and patient access should it be encountered in clinical practice.

Schedules of Controlled Substances: Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I

The DEA temporarily placed six synthetic opioids into Schedule I, impacting cannabis clinicians who may encounter these substances during patient assessments for polysubstance use or potential interactions.

Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I

The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.

Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I

This temporary scheduling action does not directly impact cannabis but clarifies federal control over fentanyl analogs, potentially affecting pain management discussions with patients considering alternatives.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

The DEA temporarily placed potent synthetic opioids N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I, impacting clinicians needing to differentiate these substances from cannabis when evaluating patient toxicology reports or altered mental status.

Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act

The DEA placed five benzodiazepine analogs into Schedule I, impacting potential clinical use and creating legal restrictions for clinicians considering these substances as alternatives or adjuncts to cannabis treatment.

Exempt Chemical Preparations Under the Controlled Substances Act

A 2023 rule clarifies that hemp-derived extracts containing no more than 0.3% delta-9 THC are exempt from Controlled Substances Act regulation, impacting legal access for some patients and clinicians.

Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I

The DEA temporarily placed seven synthetic opioids in Schedule I, impacting research and potentially diverting attention/resources from cannabis studies examining pain management alternatives.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I

The DEA placed three synthetic opioids—butonitazene, flunitazene, and metodesnitazene—into Schedule I, meaning they have a high potential for abuse and no currently accepted medical use in the United States.

These regulatory actions reflect the ongoing challenge of synthetic drug proliferation, where clandestine manufacturers continuously modify chemical structures to circumvent existing controlled substance laws. The items listed represent primarily novel synthetic cannabinoids, benzodiazepines, cathinones, and opioid analogs that have emerged in illicit drug markets faster than legislative scheduling can typically address them. From a clinical standpoint, these scheduling actions underscore the importance of maintaining awareness of novel psychoactive substances that may present to emergency departments or addiction treatment settings with unpredictable potency, toxicity profiles, and clinical effects that often differ substantially from their parent compounds.